Biohaven Ltd. AI Stock Analysis
Want to see BHVN full AI Analyst Report?
Biohaven Ltd. (BHVN) AI Stock Analysis
Biohaven Ltd.
(NYSE:BHVN)
The score is held down primarily by weak financial performance (pre-revenue, large ongoing losses and cash burn, and a deteriorated balance sheet with negative equity). Offsetting factors include strong technical momentum (price above major moving averages with positive MACD) and generally favorable corporate developments (NDA review acceptance and sizable non-dilutive licensing capital), though tempered by the partial FDA hold on BHV-7000. Valuation provides limited support due to a negative P/E and no dividend yield data.
Biohaven Ltd. (BHVN) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $2.13B
- Dividend Yield
- ―
- Average Volume (3M)
- 3.25M
- Price to Earnings (P/E)
- -3.7
- Beta (1Y)
- 1.59
- Revenue Growth
- ―
- EPS Growth
- 49.16%
- Country
- US
- Employees
- 274
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Biohaven Ltd. Business Overview & Revenue Model
Company Description
Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide. It develops BHV-1300, which is in Phase 2 clinical trial to...
How the Company Makes Money
Biohaven’s revenue model (where disclosed) has historically been driven primarily by collaboration and licensing economics rather than broad, internally built commercial product sales. Key ways the company has made money include: (1) Upfront payments...
Biohaven Ltd. Financial Statement Overview
Summary
Financials reflect a high-burn, pre-revenue profile: essentially no revenue, large and persistent net/operating losses, and deeply negative operating/free cash flow (TTM operating cash flow about -$473M). Balance-sheet risk increased as debt rose to roughly $296M and equity turned negative in TTM 2026 (about -$98M), reducing flexibility despite some improvement in losses versus the 2024 peak.
Income Statement
8Very NegativeBalance Sheet
22NegativeCash Flow
10Very Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -960.00K | -4.14M | 0 | 0 | 0 | 0 |
| EBITDA | -532.30M | -727.46M | -837.83M | -402.64M | -568.46M | -211.04M |
| Net Income | -542.68M | -738.82M | -846.42M | -408.17M | -570.28M | -213.80M |
Balance Sheet | ||||||
| Total Assets | 263.68M | 451.45M | 615.11M | 513.21M | 661.78M | 142.06M |
| Cash, Cash Equivalents and Short-Term Investments | 161.13M | 319.14M | 485.99M | 381.82M | 465.34M | 76.06M |
| Total Debt | 300.44M | 284.61M | 36.58M | 30.88M | 33.60M | 2.80M |
| Total Liabilities | 361.92M | 399.38M | 191.67M | 85.24M | 123.01M | 47.37M |
| Stockholders Equity | -98.25M | 52.07M | 423.44M | 427.98M | 538.77M | 34.69M |
Cash Flow | ||||||
| Free Cash Flow | -473.17M | -610.15M | -586.50M | -334.77M | -338.76M | -146.78M |
| Operating Cash Flow | -472.53M | -609.44M | -582.45M | -331.73M | -297.69M | -145.84M |
| Investing Cash Flow | 10.96M | 300.56M | -244.97M | 129.83M | -304.79M | 944.00K |
| Financing Cash Flow | 371.82M | 439.12M | 677.77M | 211.91M | 767.60M | 138.45M |
Biohaven Ltd. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BHVN, the sentiment is Neutral. The current price of 14.07 is below the 20-day moving average (MA) of 14.27, above the 50-day MA of 13.56, and above the 200-day MA of 12.32, indicating a neutral trend. The MACD of 0.47 indicates Positive momentum. The RSI at 49.30 is Neutral, neither overbought nor oversold. The STOCH value of 39.35 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for BHVN.
Biohaven Ltd. Risk Analysis
Biohaven Ltd. disclosed 64 risk factors in its most recent earnings report. Biohaven Ltd. reported the most risks in the "Tech & Innovation" category.
Latest Risks Added
3 New RisksBiohaven Ltd. Peers Comparison
Overall Rating
- BHVN56Neutral
RAPP51Neutral
ANRO50Neutral
CMPS48Neutral
GHRS47Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| BHVN | 56Neutral | $2.29B | -3.70 | -2271.87% | ― | ― | 49.16% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| RAPP | 51Neutral | $1.60B | -8.23 | -34.00% | ― | ― | -17.88% |
| ANRO | 50Neutral | $1.25B | -12.62 | -41.82% | ― | ― | -8.20% |
| CMPS | 48Neutral | $1.32B | -2.17 | -212.85% | ― | ― | 16.03% |
| GHRS | 47Neutral | $1.32B | -18.55 | -20.86% | ― | ― | -33.76% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| BHVN | Biohaven Ltd. | 14.07 | 5.80 | 70.13% | |
| CMPS | Compass Pathways Plc | 9.12 | 3.79 | 71.11% | |
| GHRS | Gh Research Plc | 18.49 | 4.39 | 31.13% | |
| ANRO | Alto Neuroscience, Inc. | 30.62 | 16.82 | 121.88% | |
| RAPP | Rapport Therapeutics, Inc. | 25.85 | 0.74 | 2.95% | |
| SPTX | Seaport Therapeutics, Inc. | 20.13 | 0.29 | 1.46% |
Biohaven Ltd. Corporate Events
Biohaven’s Vyglxia NDA Resubmission Gains FDA Review
PositiveOn October 22, 2026, Biohaven Ltd. announced that the U.S. Food and Drug Administration has accepted for review its resubmitted new drug application for Vyglxia (troriluzole) in spinocerebellar ataxia, following a prior action letter issued on Novemb...
Biohaven signs Asian IgG degrader licensing deal
PositiveOn October 8, 2026, Biohaven entered a strategic collaboration and license agreement with Ono Pharmaceutical granting Ono exclusive rights to develop and commercialize Biohaven’s MoDE pan IgG degrader portfolio, led by BHV‑1300 and including BHV‑1310...
Biohaven faces partial FDA hold on BHV-7000 program
NegativeIn January 2024, Biohaven completed its End-of-Phase 2 meeting with the U.S. FDA for BHV-7000, cleared the program to advance into Phase 3, and began enrolling patients in two pivotal randomized, double-blind, placebo-controlled trials in refractory...
Biohaven Licenses Kv7 Epilepsy Platform to SK Biopharmaceuticals
PositiveOn August 26, 2026, Biohaven Bioscience Ireland Limited, a subsidiary of Biohaven Ltd., entered into a strategic global licensing and collaboration agreement with SK Biopharmaceuticals for Biohaven’s Kv7 ion channel platform, led by the epilepsy cand...
Biohaven Appoints John Yetimoglu to Board of Directors
PositiveOn August 3, 2026, Biohaven Ltd.’s board appointed John Yetimoglu as a director, effective August 6, 2026, placing him in the director class whose term runs until the 2027 annual shareholder meeting and naming him to the Nominating and Governance Com...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 30, 2026